Date:8/10/2012

, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2011, and all of MultiCell's quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

'/>"/>

SOURCE MultiCell Technologies, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. CanCHEW Bio-Technologies, a Medical Marijuana Inc. Product, Dr. George Anastassov Appeared on Small Cap Voice Internet Radio Program To Discuss The CanCHEW Advantage
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. Life Technologies Announces Second Quarter 2012 Results
4. Radiation Control Technologies, Inc. Announces Exclusive License to Two Patents from the National Institutes of Health
5. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
6. Life Technologies and SATuRN Collaborate to Increase Access to HIV Testing in Africa
7. Life Technologies Develops Simplified SAME-DAY STEC Solution for Detecting Multiple Strains of E. coli in Ground Beef
8. Ellman International Launches Multi-stage Growth Plan With Acquisition Of Sandstone Medical Technologies
9. Lifeline Biotechnologies First Warning Systems
10. Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
11. Acquisition of Navigenics Expands Life Technologies Capabilities in Diagnostics